March 31st, 2017 in CIT 2017 Beijing China — BrosMed announced that it has entered into a strategic distribution agreement with Cardinal Health.
Through this distribution agreement, BrosMed Medical will significantly increase the market share and penetration of its leading family of percutaneous transluminal coronary angioplasty (PTCA) which includes Artimes™ Semi-Compliant and Apollo™ Non-Compliant coronary balloon dilatation catheters.
The agreement will initially enable Cordis, Cardinal Healths interventional vascular business, to distribute BrosMeds brand PTCA balloon dilatation catheter in mainland China. Both Artimes™ and Apollo™ products which have obtained CFDA and CE approval and FDA clearance are manufactured in China and being sold globally.
“The agreement between BrosMed Medical and Cardinal Health is an extremely important milestone in our continuing strategy to deepen our market penetration and expand as well as diversify our products offering and service” said Benny Lee, Chairman of BrosMed Medical. “Working together with Cardinal Health shall be able to leverage our joint capabilities of delivering state-of-art products including Artimes™ and Apollo™ PTCA, while maximizing the increased market coverage in the Mainland China through geographical footprint of BrosMed Medical and Cordis franchises.”
“Our PTCA portfolio covers semi-compliant, non-compliant and CTO 1.0mm balloon catheters, the products are being sold in thirty (30) countries and territories, including USA , China and EU, those are well received in the market and acknowledged by top key opinion leader (KOL). BrosMed dedicate ourselves to the new products and technology in order to consistently provide high quality products and services to the cardiovascular and endovascular patients around the world.” said Stephen Lee, General Manager of BrosMed Medical.
Exhibitor Data Sheet